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Background. Gene expression profiling has revolutionized our ability to molecularly classify primary human tumors and
significantly enhanced the development of novel tumor markers and therapies; however, progress in the diagnosis and
treatment of melanoma over the past 3 decades has been limited, and there is currently no approved therapy that significantly
extends lifespan in patients with advanced disease. Profiling studies of melanoma to date have been inconsistent due to the
heterogeneous nature of this malignancy and the limited availability of informative tissue specimens from early stages of
disease. Methodology/Principle Findings. In order to gain an improved understanding of the molecular basis of melanoma
progression, we have compared gene expression profiles from a series of melanoma cell lines representing discrete stages of
malignant progression that recapitulate critical characteristics of the primary lesions from which they were derived. Here we
describe the unsupervised hierarchical clustering of profiling data from melanoma cell lines and melanocytes. This clustering
identifies two distinctive molecular subclasses of melanoma segregating aggressive metastatic tumor cell lines from less-
aggressive primary tumor cell lines. Further analysis of expression signatures associated with melanoma progression using
functional annotations categorized these transcripts into three classes of genes: 1) Upregulation of activators of cell cycle
progression, DNA replication and repair (CDCA2, NCAPH, NCAPG, NCAPG2, PBK, NUSAP1, BIRC5, ESCO2, HELLS, MELK, GINS1,
GINS4, RAD54L, TYMS, and DHFR), 2) Loss of genes associated with cellular adhesion and melanocyte differentiation (CDH3,
CDH1, c-KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R, and OCA2), 3) Upregulation of genes associated with resistance to
apoptosis (BIRC5/survivin). While these broad classes of transcripts have previously been implicated in the progression of
melanoma and other malignancies, the specific genes identified within each class of transcripts are novel. In addition, the
transcription factor NF-KB was specifically identified as being a potential ‘‘master regulator’’ of melanoma invasion since NF-KB
binding sites were identified as consistent consensus sequences within promoters of progression-associated genes.
Conclusions/Significance. We conclude that tumor cell lines are a valuable resource for the early identification of gene
signatures associated with malignant progression in tumors with significant heterogeneity like melanoma. We further
conclude that the development of novel data reduction algorithms for analysis of microarray studies is critical to allow for
optimized mining of important, clinically-relevant datasets. It is expected that subsequent validation studies in primary human
tissues using such an approach will lead to more rapid translation of such studies to the identification of novel tumor
biomarkers and therapeutic targets.
Citation: Ryu B, Kim DS, DeLuca AM, Alani RM (2007) Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of
Melanoma Progression. PLoS ONE 2(7): e594. doi:10.1371/journal.pone.0000594
INTRODUCTION
The incidence of melanoma is increasing at one of the highest
rates for any form of cancer in the United States [1]. At present,
there are no systemic agents available that significantly extend the
lifespan of patients with advanced disease, and the key to
improved survival in all affected individuals remains early
diagnosis and treatment. While early stage disease may result in
occasional deaths, there are no available tests to predict which
early stage tumors have a high likelihood of progression and
therefore a worse prognosis. Thus, an urgent need exists for the
identification of molecular signatures of melanoma progression
which can be used to develop accurate prognostic markers and
effective targeted therapies. High-throughput gene expression
profiling technologies offer an opportunity to uncover critical
molecular events in the development and progression of human
melanoma and can be used to design improved prognostic testing
and effective treatment strategies. Previous transcriptome analyses
in other malignancies have provided valuable information for the
assessment of patient group classifications such as subgroups of
patients that are likely to respond to a particular therapy [2].
Expression profiling of metastatic melanomas was able to identify
previously unrecognized subtypes of disease and predict pheno-
typic characteristics which may be of importance to melanoma
progression [3]. Further studies using serial analysis of gene
expression (SAGE) and cDNA arrays have yielded the identifica-
tion of additional novel molecules and pathways which may be
involved in melanoma development[4–7]. Such studies have been
limited in utility due to the lack of concordance from one study to
the next suggesting tumor heterogeneity [8]. In addition, the
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has hindered the ability to identify serial molecular events that lead
to melanoma onset. This shortcoming of tissue availability has
largely restricted gene expression profiling studies in melanoma to
the use of small numbers of established tumor cell lines and cases
of metastatic disease.
Previous studies of primary human melanomas have identified
gene signatures associated with tumor progression [9–11]. These
signatures included upregulation of cell cycle regulatory proteins,
mitotic checkpoint genes, genes involved in DNA replication and
repair, and cellular stress response genes in addition to loss of
genes promoting apoptosis; however, few of the genes identified
in these studies were concordant suggesting limitations due to
tumor variability. Since better knowledge of gene expression
signatures associated with melanoma progression may identify
improved screening tools and therapeutic strategies, we used high
density cDNA microarrays for gene expression profiling of
genetically well-defined melanoma cell lines isolated from
distinctive stages of tumor progression. Novel data reduction
algorithms were used to identify gene signatures associated with
tumor invasion and metastasis. Here we report unique sets of
gene expression signatures that are associated with melanoma
progression. Many of these pathways have previously been
implicated in melanoma progression; however, the specific
signature genes identified are novel. These particular pro-
gression-associated genes may reflect the underlying molecular
mechanisms of the various phases in the known tumor pro-
gression pathways of melanoma. As such, the pathways and
molecules identified in this study have the potential to be utilized
as therapeutic targets for melanoma as well as novel molecular
markers for melanoma progression. Moreover, these studies
support the use of renewable sources of tumor cells, such as
informative tumor cell lines, for the early identification of genes
associated with malignant progression which can be subsequently
validated using more precious primary tissue specimens.
RESULTS
In order to define gene expression patterns during the course of
melanoma development and progression, we evaluated a series of
primary and metastatic melanoma cells derived from lesions of
discrete phases of melanoma progression as well as pools of
primary human melanocytes. Tumor cell lines derived from three
radial growth phase (RGP) melanomas (WM35, SBC12, and
WM1552C), four vertical growth phase (VGP) melanomas
(WM902B, WM278, WM983A, and WM793), and three
metastatic melanomas (WM852, WM983B, 1205Lu) were evalu-
ated. These cell lines possess a notable ability to recapitulate the
clinical stages of disease from which they were derived [12,13] and
have been characterized with respect to tumorigenicity and
metastasis [14–17]; cellular growth characteristics including life
span, growth factor dependency, anchorage-independent growth
[12]; and pigmentation and morphology [18]. In addition,
cytogenetic analyses in these cell lines including non-random
abnormalities such as deletions, translocations, and amplifications
have been well-documented and suggest high relevance to the
primary tumor of origin (reviewed in [12]).
Global gene expression patterns were obtained using Affymetrix
gene chips and comparison of gene expression profiles was
performed using hierarchical clustering analysis. This clustering
analysis identified two distinct groups of melanoma cell lines based
on the similarity of their expression patterns, separating radial
growth phase (RGP) and metastatic melanomas (MM) (Figure 1);
however, vertical growth phase (VGP) melanomas failed to form
a distinctive cluster (Figure 1A). The first group, which we
characterized as ‘‘less-aggressive’’ primary melanomas (designated
as Group1), included all three RGP melanomas (WM35, Sbcl2,
and WM1552C) and two VGP melanomas (WM902B and
WM278). The second group, which we characterized as ‘‘more-
aggressive’’ melanomas (designated as Group2), included all three
metastatic melanomas (WM853, WM983B, and 1205Lu) and two
VGP melanomas (WM983B and WM793). Additional cluster
analyses with different linkage matrices produced similar results
(data not shown). Of note, only 2 of the 10 cell lines (Sbcl2 and
WM853) were found to be wildtype for BRAF kinase and this
genotype failed to demonstrate a notable cluster in our
hierarchical analyses.
In order to identify a cohort of genes differentially expressed
between our defined groups of melanomas, the gene expression
array dataset was subjected to the microarray data analysis
program Significance Analysis of Microarray (SAM) [19]. This
analysis resulted in 142 differentially expressed probesets with a 3.5
% false discovery rate (Figure 1B and C). In total, 89 probe sets
representing 65 well-defined genes were found to be upregulated
in more-aggressive (group 2) versus less-aggressive (group 1)
melanomas and 53 probe sets representing 37 well-defined genes
were found to be downregulated (Table S1). When more stringent
criteria were applied (well-characterized genes which are differ-
entially expressed greater than 4-fold) to this signature, we
identified 21 upregulated and 5 downregulated genes in the
more-aggressive melanoma cells (Figure 1C). Of note, the set of
genes highly expressed in more-aggressive melanomas includes
many novel genes with reported functional roles in cell cycle
regulation and proliferation such as ZWINT, CDCA2, NCAPH,
NCAPG, NCAPG2, PBK, NUSAP1, BIRC5, ESCO2, HELLS, MELK,
and CDKN2C [20–31] as well as genes that are involved DNA
replication and repair processes including GINS1, GINS4, RAD54L,
TYMS, and DHFR [32–34] (Table 1). Differential expression of
these genes was validated by quantitative real-time RT-PCR
(Figure 1D).
Since we were interested in defining melanoma progression
signatures, and all melanomas are initiated in primary human
melanocytes, we evaluated our expression profiling data in the
context of cultured neonatal primary human melanocytes
(Figure 2). Surprisingly, when two pools of short-term cultured
primary human melanocytes (HPM1 and HPM2) were included in
the previously employed hierarchical clustering protocol, the
global gene expression pattern of the normal melanocytes was
found to be more similar to that of the more-aggressive melanomas
(Group 2) than the less-aggressive melanomas (Group 1)
(Figure 2A). Since early cultures of primary human melanocytes
derived from neonatal foreskins divide rapidly yet possess a normal
differentiation program, we reasoned that the similarities of these
cells to more aggressive tumors was likely due to their proliferative
potential. In order to test this hypothesis we compared gene
expression profiles of more-aggressive melanoma cells (Group 2) to
those of short-term cultured primary human melanocytes.
Expression profiles were subjected to SAM analysis which
identified a cohort of differentially expressed genes with a 0.85%
false discovery rate. Remarkably, all differentially expressed genes
were found to be down-regulated genes in aggressive melanoma
cells versus primary human melanocytes suggesting that loss of
specific gene signatures may be a key event in the development of
advanced melanomas (Figure 2B). Further assessment of all
melanoma expression profiles using TreeView revealed that the
majority of these melanoma-associated genes are also down-
regulated in the less-aggressive primary melanomas (Group1)
(Figure 2C). This gene signature is comprised of critical mediators
of cellular adhesion and melanocyte development and differenti-
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TYR, MELANA, MC1R, and OCA2 [35–42] (Table 2). While such
a loss of cellular adhesion by E-cadherin and P-cadherin has been
extensively documented in melanoma (reviewed in [43]), and the
loss of differentiation-associated genes is not wholly surprising, this
signature does notably identify specific defects in the intrinsic
melanocyte development program that may contribute to
melanoma development. In addition, genes with tumor suppressor
and metastasis suppressor functions (DPP4, SYK) are included in
this melanoma signature [44,45]. Significant down-regulation of
these genes in the aggressive metastatic melanoma cells was
validated using semi-quantitative duplex RT-PCR (Figure 2D).
Furthermore, this differentially expressed ‘‘melanoma signature’’
contains many genes whose functional roles in melanoma
progression have not been well characterized and may provide
novel insights into the early development of melanoma from
primary melanocytes.
A current melanoma progression model suggests the sequential
evolution of primary in situ tumors and minimally invasive tumors
which are termed ‘‘radial growth phase’’, followed by a subsequent
conversion to a more aggressive ‘‘vertical growth phase’’, in which
tumor cells are programmed to cross the epidermal basement
membrane and invade vertically into the dermis. It has been
postulated that the VGP is the critical stage in which a tumor gains
metastatic capacity. We therefore compared the gene expression
profiles of RGP and VGP melanomas using a uniquely designed
data reduction algorithm in order to identify genes that are likely
to be relevant to this critical invasive phenotype (Figure 3A). Our
Figure 1. Evaluation of gene expression profiles from melanoma cells lines of varying stages of progression identifies a signature for aggressive
melanomas. A) Unsupervised hierarchical clustering of melanoma cells indicates the existence of two distinct groups of melanoma cells based on
global gene expression patterns (Group 1: RGP2, RGP3, RGP1, VGP1, and VGP2; Group 2: VGP3, MM2, MM1, VGP4, and MM3). B) SAM plot sheet
illustrating a signature for differentially expressed genes in aggressive melanomas. Gene expression profiles from the two groups of melanomas were
compared (Group1 vs. Group 2) and a differentially expressed gene signature was identified by SAM. Red and green dots represent gene probesets
upregulated and downregulated respectively in Group 2. C) The melanoma gene signature was visualized using Java TreeView. Genes over four-fold
differentially expressed are indicated on the right side of the image. D) Validation of select differentially expressed genes by real-time RT-PCR. Three
genes upregulated in aggressive melanomas (Group 2) were selected for analysis and their differential expression was verified. 3.0 mg of total RNA
was subjected to cDNA synthesis reaction as described in the materials and methods. 1.0 ml of the final cDNA samples (100 ml) were used for real-
time Q-PCR reaction. For the measurement of gene transcript level, standard curves were generated for each gene using known amount of PCR
amplified product from the corresponding genes. Error bars are SD of three independent experiments.
doi:10.1371/journal.pone.0000594.g001
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PLoS ONE | www.plosone.org 3 July 2007 | Issue 7 | e594melanoma invasion-specific signature is notably characterized by
the inclusion of several genes involved in chemotaxis and the
inflammatory response (CXCL1, CXCL2, IL8, and IL6), cell
adhesion (HNT, ITGA4, ITGB8, CSPG2, ZP4, and FLRT3), and
extracellular matrix organization (MMP1, COL4A1, COL4A2, and
COL5A2) (Table 3). These genes and their relative expression
profiles are depicted in Figure 3B. These cellular processes have
previously been implicated in tumor progression for a wide variety
of malignancies including melanoma and are felt to be essential
components of tumor invasion and metastasis. In addition, many
of these invasion-specific signature genes are also upregulated in
metastatic melanomas (Figure 3B). The differential expressions
were validated on the selected genes using semi-quantitative
duplex-PCR analysis (Figure 3C).
Since the melanoma invasion-specific signature was associated
with common functions of matrix invasion/inflammation/cell
migration we sought to determine whether a common upstream
regulatory pathway might link these signature genes. The eight
most highly up-regulated genes from our melanoma invasion-
specific signature were selected for further evaluation and gene
promoter sequences were analyzed to identify transcription factor
binding cis elements. This promoter analysis yielded a profile of
transcription factors with common sequence elements in the
signature genes. The most ubiquitous cis elements among the gene
promoters evaluated were E12, E47, GCN4, GR, HES-1, IL-6,
MEF-2, NF-KB, N-Oct-3, PU.1, RAR-alpha1, SRF, and the basal
gene transcriptional complex components of TFIID, TBP, and
TBF1. We notably identified the NF-KB binding sequence in 7 out
of 8 of the most upregulated invasion-specific signature genes
(Figure 3D). We were particularly interested in the NF-KB
pathway as a mediator of melanoma invasion since our most
highly upregulated invasion-specific genes, CXCL-1 and IL-8, have
previously been reported to be activated by NF-KB and had
previously been implicated in melanoma progression (reviewed in
[46]). Given the consequences of NF-KB activation in a cell, NF-
KB function is highly regulated by specific cytosolic inhibitory
activities which prevent inappropriate NF-KB activation and
shuttling to the nucleus. Thus, only nuclear NF-KB is considered
to be functionally activated. In order to evaluate NF-KB function
in our tumor cell lines, we used NF-KB cellular localization as
a surrogate marker for NF-KB activity. We find that invasive
(VGP) melanomas posses both cytosolic (inactive) and nuclear
(active) localization of NF-KB, while non-invasive (RGP) melano-
mas possess NF-KB confined to the cytosolic compartment
suggesting specific activation of NF-KB during melanoma pro-
gression (Figure 3E).
Table 1. Genes with altered expression in aggressive melanoma cells are involved in cell cycle control, cell proliferation, DNA repair
and replication
a.
..................................................................................................................................................
Probe Set ID Gene Title Gene Symbol Fold
b Function
227350_at Helicase, lymphoid-specific HELLS
c 8.5 cell proliferation
202589_at thymidylate synthetase TYMS 7.2 DNA replication, DNA repair
204558_at RAD54-like (S. cerevisiae) RAD54L 6.2 DNA repair, response to DNA
damage
204825_at maternal embryonic leucine
zipper kinase
MELK 5.9 Mitosis, protein phosphorylation
204159_at cyclin-dependent kinase
inhibitor 2C (p18)
CDKN2C 5.8 cell cycle
212949_at barren homolog 1 (Drosophila)NCAPH 5.8 cell cycle, chromosome
condensation
219588_s_at leucine zipper protein 5 NCAPG2 4.6 cell cycle, chromosome
condensation
218663_at chromosome condensation
protein G
HCAPG1 4.5 cell cycle, chromosome
condensation
211767_at GINS complex subunit 4 (Sld5
homolog)
GINS4 5.6 DNA replication, cell proliferation
206102_at GINS complex subunit 1 (Psf1
homolog)
GINS1 4.7 DNA replication, cell proliferation
202095_s_at baculoviral IAP repeat-
containing 5
BIRC5 5.1 G2/M transition cell cycle
219148_at PDZ binding kinase PBK 5.1 mitosis, protein phosphorylation
235178_x_at establishment of cohesion 1
homolog 2
ESCO2 5.1 cell cycle
226661_at cell division cycle associated 2 CDCA2
c 4.9 cell cycle
204026_s_at ZW10 interactor ZWINT 4.7 cell cycle, spindle organization
202534_x_at dihydrofolate reductase DHFR 4.5 DNA replication, nucleotide metab
olism
218039_at nucleolar and spindle
associated protein 1
NUSAP1 4.1 cell cycle, chromosome
condensation
1555788_a_at tribbles homolog 3 (Drosophila)TRIB3
c 26.7 anti-proliferation, apoptosis
aGenes with greater than four-fold differential expression are shown.
bFold represents average expression ratio of group 2 over Group1.
cGenes with multiple probesets are shown with data from a single representative probeset.
doi:10.1371/journal.pone.0000594.t001
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Molecular profiling studies of melanoma to date have been
variably successful and often inconsistent. Much of this in-
consistency has been attributed to the heterogeneous nature of
this malignancy and the lack of significant sources of meaningful
archived tissue specimens for analysis. In addition, variable
sample preparation techniques are also likely to lead to disparate
results between investigators. Here we have used a series of well-
defined melanoma cell lines from varying stages of malignant
progression to assess molecular signatures associated with disease
progression. These cell lines have undergone extensive charac-
terization of their tumorigenic potential and invasion capacity
[14,47], and have been shown to possess a remarkable ability to
recapitulate the clinical stages of disease from which they were
derived. We show that unsupervised hierarchical clustering of
global gene expression profiles of melanoma cell lines allows for
the classification of tumor cells into 2 groups (Figure 1A) that we
have defined as less-aggressive (Group 1) and more-aggressive
(Group 2) melanomas. While all radial growth phase melanomas
clustered in Group 1, and all metastatic melanomas clustered in
Group 2, vertical growth phase melanomas failed to form
a distinctive cluster suggesting that vertical growth phase
melanomas may be considered to be a transient or transition
phase within the current melanoma progression model [48].
Aggressive (Group 2) melanomas were characterized by upregu-
lation of genes associated with cell cycle progression, DNA
replication and repair, and altered expression of apoptosis-
related genes including upregulation of the antiapoptotic gene
BIRC5/survivin [49] and downregulation of the novel stress-
associated apoptosis inducer TRIB3 [50] (Table 1). These
signature genes for melanoma progression are remarkably similar
to those obtained from recent large-scale studies using primary
human melanomas and suggest high correlation with alterations
seen in primary tumor specimens [10]. Notably, we did not
identify a dominant signature associated with BRAF kinase
mutations which may be reflective of the relative infrequency of
wildtype BRAF in these cell lines. As a whole, this gene signature
suggests a series of molecular alterations occur in aggressive
melanomas that promote melanoma cell growth, survival and
apoptotic resistance which contribute to the unresponsiveness of
melanomas to traditional chemotherapeutic agents [51].
Figure 2. Evaluation of differential gene expression from aggressive melanomas (Group 2) vs. primary human melanocytes identifies a signature
characterized by loss of differentiation-associated genes. A) Java TreeView analysis of melanoma cell lines and primary human melanocytes
clusters two pools of human primary melanocytes (HPM1 and HPM2) with the Group 2 melanomas. B) SAM plot sheet illustrating a signature of
down-regulated genes in group 2 melanomas compared to HPMs. Gene expression profiles of two pools of human primary melanocytes (HPM1 and
HPM2) were compared to those of aggressive melanomas (Group 2) and a differentially expressed gene signature was identified by SAM. C) The
melanoma gene signature was visualized using Java TreeView. Genes over five-fold downregulated are indicated on the right. D) Validation of
differential expression for selected genes by semi-quantitative duplex RT-PCR. Four genes (CDH3, KIT, DPP4, SYK) downregulated in the aggressive
melanoma cells (Group 2) were selected for analysis and their differential expression was verified.
doi:10.1371/journal.pone.0000594.g002
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PLoS ONE | www.plosone.org 5 July 2007 | Issue 7 | e594Table 2. Differential expression of genes that are downregulated in aggressive melanoma cells (Group2) compared to primary
human melanocytes. Genes with greater than five-fold differential expression are shown
a.
..................................................................................................................................................
Probe Set ID Gene Title Gene Symbol Fold
b Function
203256_at cadherin 3, type 1, P-cadherin (placental) CDH3 2161.9 cell adhesion
201131_s_at cadherin 1, type 1, E-cadherin (epithelial) CDH1
c 235.1 cell adhesion
205051_s_at v-kit viral oncogenehomolog KIT 294.0 signal transduction
1565162_s_at microsomal glutathione S-transferase 1 MGST1
c 292.5 —
203716_s_at dipeptidyl-peptidase 4 (CD26) DPP4
c 274.0 proteolysis
206039_at RAB33A, member RAS oncogene family RAB33A 270.4 signal transduction
226311_at CDNA clone IMAGE: 30924414 — 264.3 —
236901_at ADAM metallopeptidase ADAMTS2 262.1 proteolysis
229095_s_at similar to LIM LOC440895 254.6 —
227705_at transcription elongation factor A (SII)-like 7 TCEAL7 249.1 —
1556698_a_at hypothetical protein LOC285513 LOC285513 235.0 —
213924_at metallophosphoesterase 1 MPPE1 233.5 —
209569_x_at DNA segment on chromosome 4 D4S234E
c 231.6 dopamine receptor signaling
202283_at serpin peptidase inhibitor, clade F, member 1SERPINF1 229.2 development/proliferation
204570_at cytochrome c oxidase subunit VIIa
polypeptide 1
COX7A1 228.8 electron transport
202546_at vesicle-associated membrane protein 8 VAMP8 227.9 vesicle-mediated transport
208017_s_at MCF.2 cell line derived transforming
sequence
MCF2
c 227.8 intracellular signaling cascade
217248_s_at solute carrier family 7, member 8 SLC7A8
c 227.1 amino acid transport
206479_at transient receptor potential cation channel TRPM1 225.8 cation transport
205114_s_at chemokine (C-C motif) ligand 3 CCL3 225.6 chemotaxis/inflammatory
220813_at cysteinyl leukotriene receptor 2 CYSLTR2 225.3 signal transduction
206355_at G protein, alpha activating activity
polypeptide
GNAL
c 223.5 signal transduction
237472_at SRY (sex determining region Y)-box 1 SOX1 223.4 regulation of transcription
203815_at glutathione S-transferase theta 1 GSTT1 222.1 response to stress
212599_at autism susceptibility candidate 2 AUTS2 220.3 —
206426_at melan-A MLANA 220.3 —
225407_at myelin basic protein MBP
c 219.7 CNS development
219436_s_at endomucin EMCN 219.4 —
1556427_s_at similar to hypothetical protein LOC221091 217.9 —
201425_at aldehyde dehydrogenase 2 family
(mitochondrial)
ALDH2 217.8 carbohydrate metabolism
207144_s_at Cbp/p300-interacting transactivator 1 CITED1 217.7 regulation of transcription
212338_at myosin ID MYO1D 217.7 —
219315_s_at chromosome 16 open reading frame 30 C16orf30 217.0 —
227532_at leucine rich repeat containing 39 LRRC39 216.5 —
206569_at interleukin 24 IL24 216.1 apoptosis/immune response
226068_at spleen tyrosine kinase SYK
c 215.9 signal transduction
213122_at TSPY-like 5 TSPYL5 215.8 nucleosome assembly
204187_at guanosine monophosphate reductase GMPR 214.7 nucleic acid metabolism
204880_at O-6-methylguanine-DNA methyltransferase MGMT 214.3 DNA repair
204777_s_at mal, T-cell differentiation protein MAL 214.2 cell differentiation
1555505_a_at tyrosinase (oculocutaneous albinism IA) TYR 213.6 melanin biosynthesis
226778_at chromosome 8 open reading frame 42 C8orf42
c 213.1 —
225792_at hook homolog 1 (Drosophila) HOOK1 212.5 cytoskeleton organization
209924_at chemokine (C-C motif) ligand 18 CCL18 211.8 chemotaxis/inflammatory
211427_s_at potassium inwardly-rectifying channel, KCNJ13 211.7 ion transport
213556_at similar to R28379-1 LOC390940 211.7 —
240173_at transcribed locus — 211.5 —
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PLoS ONE | www.plosone.org 6 July 2007 | Issue 7 | e594While gene signatures associated with aggressive melanomas
provide insights into molecular pathways important for tumor
progression, further analysis of these tumor cell lines in conjunction
with expression profiles from primary human melanocytes using
SAM analysis revealed a striking signature characterized exclusively
by gene loss in melanomas and primarily by loss of cellular adhesion
and melanocyte differentiation-associated genes (Figures 2B, 2C).
We suggest that this melanoma-associated signature defines critical
molecular mechanisms involved in melanocyte development and
differentiation which distinguish these tumor cells from their
primary cell of origin. In fact, the identification of several genes in
this signature with established functional roles in melanocyte
differentiation and melanin biosynthesis such as CDH3, CDH1, c-
KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R, and OCA2
[35–42], supports this notion. Moreover, this signature has
identified two tumor suppressor genes, DPP4 and SYK, whose
downregulation has previously been implicated in melanoma
development [52–54].
Finally, evaluation of an invasion-specific signature for mela-
noma identified dominant gene activation by the transcription
factor, NF-KB. Constitutive activation of NF-KB and an in-
flammatory response is an emerging hallmark of various tumor
types [55]. In addition, NF-KB has specifically been implicated in
the development of invasive aggressive melanomas through
autocrine and paracrine mechanisms (reviewed in [46]). Our
melanoma invasion signature is associated with upregulation of
Probe Set ID Gene Title Gene Symbol Fold
b Function
206498_at oculocutaneous albinism II OCA2 211.4 eye pigment biosynthesis
241600_at transcribed locus — 211.0 —
205297_s_at CD79b molecule, immunoglobulin-
associated
CD79B 210.9 immune response
228256_s_at erythrocyte membrane protein band 4.1 like
4A
EPB41L4A 210.9 —
223693_s_at hypothetical protein FLJ10324 FLJ10324 210.3 signal transduction
243727_at copine VIII CPNE8 210.1 —
232687_at CDNA FLJ33091 fis, clone TRACH2000660 — 29.9 —
232443_at hypothetical gene supported by AF131741 LOC441052 29.9 —
236377_at transmembrane protein 132D TMEM132D 29.1 —
211748_x_at prostaglandin D2 synthase 21kDa (brain) PTGDS 29.0 lipid biosynthesis
204112_s_at histamine N-methyltransferase HNMT 28.7 respiratory gaseous exchange
228057_at DNA-damage-inducible transcript 4-like DDIT4L 28.6 —
51158_at hypothetical gene LOC400451 28.3 —
209550_at necdin homolog (mouse) NDN 28.3 regulation of cell cycle
214255_at ATPase, Class V, type 10A ATP10A 27.9 cation transport
1553485_at hypothetical protein LOC151278 FLJ32447 27.8 —
204273_at endothelin receptor type B EDNRB 27.6 G-protein signaling
235758_at paraneoplastic antigen like 6A PNMA6A 27.6 —
213816_s_at met proto-oncogene MET 27.2 cell proliferation
227704_at full-length cDNA clone CS0CAP008YI07 — 27.1 —
224566_at trophoblast-derived noncoding RNA TncRNA 26.9 —
207610_s_at EGF-like module containing, mucin-like EMR2 26.8 signal transduction
232504_at hypothetical protein LOC285628 LOC285628 26.8 —
241966_at myosin VA (heavy polypeptide 12, myoxin) MYO5A
c 26.7 actin-based movement
229925_at solute carrier family 6, member 17 SLC6A17 26.6 neurotransmitter transport
229251_s_at two pore segment channel 2 TPCN2
c 26.2 cation transport
216059_at paired box gene 3 (Waardenburg syndrome
1)
PAX3
c 26.2 development
227949_at phosphatase and actin regulator 3 PHACTR3 25.7 —
209685_s_at protein kinase C, beta 1 PRKCB1 25.6 intracellular signaling cascade
204995_at cyclin-dependent kinase 5, regulatory
subunit 1
CDK5R1 25.3 neuron differentiation
206020_at suppressor of cytokine signaling 6 SOCS6 25.0 regulation of cell growth
221036_s_at anterior pharynx defective 1 homolog B APH1B 25.0 Notch signaling pathway
205458_at melanocortin 1 receptor MC1R 25.0 G-protein signaling
aGenes with greater than five-fold differential expression are shown.
bFold represents average expression ratio of aggressive metastatic melanoma samples (group2) over normal primary human melanocyte samples.
cGene with multiple probesets are shown with a representative probeset.
doi:10.1371/journal.pone.0000594.t002
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PLoS ONE | www.plosone.org 7 July 2007 | Issue 7 | e594critical NF-KB effectors including CXCL1, FMN2, MMP1, IL-8,
IGFBP3 which have been implicated in the regulation of tumor
cell proliferation, motility, migration, and/or invasion (Figure 3D).
In addition, the putative NF-KB target gene GAGE7B which we
identified in our melanoma invasion-specific signature, has been
associated with apoptotic resistance and worse prognosis in other
tumors [56]. In addition, several of our invasion-specific signature
genes are chemokines including CXCL1, CXCL2, and IL-8 which
have been implicated in the promotion of tumor-associated
angiogenesis, a critical feature of invasive tumors [57].
In summary, our gene expression profiling studies of melanoma
cell lines from varying stages of malignant progression and
primary human melanocytes have identified several important
melanoma signatures including: 1) Aggressive melanomas are
characterized by upregulation of genes associated with cell cycle
progression, DNA replication and repair and apoptotic resistance
as well as loss of genes associated with apoptotic susceptibility, 2)
Melanomas notably differ from their cell of origin, primary human
melanocytes, due to a loss of cellular adhesion and differentiation-
associated genes, and 3) Invasive melanomas are characterized by
a signature indicative of global activation of NF-KB and
downstream effector genes associated with tumor cell migration,
invasion, chemotaxis, and proliferation. Since pathways associated
with tumor progression may have clinical utility as prognostic
tumor markers and therapeutic targets, we expect novel melanoma
signature genes identified in this study will be further developed for
such translational endpoints. Moreover, the important information
regarding melanoma biology gleaned from these studies on
renewable cell resources cannot be understated. A major
roadblock to advances in melanoma therapy has been the relative
paucity of informative tissue specimens available for analysis in
profiling studies as well as the notoriously heterogeneous nature of
this malignancy. The use of surrogate tissue resources including
tumor cell lines for the early discovery phases in melanoma, as
used in this study, will undoubtedly allow for the conservation of
precious tissue specimens for use in more advanced validation
studies. It is expected that the novel melanoma progression-
associated genes identified in this study will provide new insights
into the molecular defects associated with this malignancy and
ultimately pave the way for the development of new melanoma
biomarkers and novel targeted therapies.
MATERIALS AND METHODS
Cells
Ten melanoma cell lines (WM35, SBC12, and WM1552C,
WM902B, WM278, WM983A, and WM793, WM852,
WM983B, 1205Lu) were obtained from M. Herlyn (The Wistar
Institute, Philadelphia, PA). These cell lines were maintained in
modified complete melanocyte growth medium (Cell Application
Inc., San Diego, CA) which lacked 12-O -tetradecanoyl phorbol-
13-acetate and was supplemented with 2 % fetal bovine serum.
Figure 3. Identification of an invasion-specific gene signature for melanoma. A) The three-step data reduction algorithm used for identification of
a melanoma invasion-specific signature. (see detailed description in Data Extraction and Statistical Analysis section of Methods). B) Relative
expression levels of melanoma invasion-specific signature genes in all cells analyzed including human primary melanocytes (HPM1, HPM2). C)
Validation of differential expression for selected genes by semi-quantitative duplex RT-PCR. Four genes (IL-8, IGFBP3, CXCL1, CXCL2) that are
upregulated in invasive melanomas were selected and their differential expression was verified. D) Promoter analysis of selected genes from the
melanoma invasion-specific signature identifies putative NF-KB binding cis elements. E) Immunofluorescence staining of NF-KB in invasive (WM902B)
vs. non-invasive (WM1552C) melanoma cells demonstrates constitutive activation and nuclear trafficking of NF-KB in invasive melanomas.
doi:10.1371/journal.pone.0000594.g003
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PLoS ONE | www.plosone.org 8 July 2007 | Issue 7 | e594Table 3. Melanoma invasion-specific signature genes that are upregulated in VGP compared to RGP melanoma cells
a.
..................................................................................................................................................
Probe Set ID Gene Title Gene Symbol Fold
b Biological Process
204470_at chemokine (C-X-C motif) ligand 1 CXCL1 62.3 chemotaxis/inflammatory
1555471_a_at formin 2 FMN2 38.8 development
204475_at matrix metallopeptidase 1 MMP1 34.2 proteolysis/ECM organization
202196_s_at dickkopf homolog 3 (Xenopus laevis) DKK3
c 24.5 Wnt receptor signaling
208894_at major histocompatibility complex, class II, DRa HLA-DRA 21.6 immune response
211506_s_at interleukin 8 IL8
c 19.9 chemotaxis/inflammatory
212730_at desmuslin DMN 17.6 —
210095_s_at insulin-like growth factor binding protein 3 IGFBP3
c 17.5 regulation of cell growth
206640_x_at G antigens GAGEs 15.5 cellular defense response
227566_at neurotrimin HNT 15.2 cell adhesion
212327_at hypothetical protein DKFZP686A01247
c — 14.8 actomyosin structure
211776_s_at erythrocyte membrane protein band 4.1-like 3 EPB41L3 13.3 cytoskeleton organization
221729_at collagen, type V, alpha 2 COL5A2 12.7 ECM organization
226189_at integrin, beta 8 ITGB8 12.4 cell-matrix adhesion
226847_at follistatin FST
c 11.4 development
222450_at transmembrane, prostate androgen induced RNA TMEPAI
c 11.3 androgen receptor signaling
212942_s_at KIAA1199 KIAA1199 11.2 sensory perception of sound
205207_at interleukin 6 (interferon, beta 2) IL6 11.0 immune response/inflammatory
209619_at CD74 molecule, major histocompatibility complex CD74 10.7 immune response
211571_s_at chondroitin sulfate proteoglycan 2 (versican) CSPG2
c 10.3 cell adhesion/development
223614_at chromosome 8 open reading frame 57 C8orf57 10.3 —
207030_s_at cysteine and glycine-rich protein 2 CSRP2
c 10.0 muscle development
229800_at Doublecortin and CaM kinase-like 1 DCAMKL1 10.0 nervous system development
211538_s_at heat shock 70kDa protein 2 HSPA2 9.9 protein folding
223638_at neuroblastoma breakpoint family, member 3 NBPF3 9.9 —
209312_x_at major histocompatibility complex, class II, DR b1 HLA-DRB1
c 9.6 immune response
1561691_at hypothetical protein LOC285735 LOC285735 9.0 —
209774_x_at chemokine (C-X-C motif) ligand 2 CXCL2 8.6 chemotaxis/inflammatory
209392_at pyrophosphatase/phosphodiesterase 2 ENPP2
c 8.3 cell motility/chemotaxis
231756_at zona pellucida glycoprotein 4 ZP4 7.8 fertilization/cell adhesion
209309_at alpha-2-glycoprotein 1, zinc AZGP1 7.7 cell adhesion
241803_s_at — — 7.4 —
204469_at protein tyrosine phosphatase, receptor-type, Z PTPRZ1 7.2 nervous system development
205885_s_at integrin, alpha 4 ITGA4 7.2 cell adhesions
228293_at DEP domain containing 7 DEPDC7 7.0 regulation of transcription
213075_at olfactomedin-like 2A OLFML2A 7.0 —
219230_at transmembrane protein 100 TMEM100 7.0 —
204681_s_at Rap guanine nucleotide exchange factor 5 RAPGEF5 6.6 signal transduction
211980_at collagen, type IV, alpha 1 COL4A1 6.4 ECM organization
211991_s_at major histocompatibility complex, class II, DP a1 HLA-DPA1 6.3 immune response
216959_x_at neuronal cell adhesion molecule NRCAM 6.3 neuron cell adhesion
209967_s_at cAMP responsive element modulator CREM 6.2 signal transduction
222162_s_at ADAM metallopeptidase ADAMTS1 6.1 proteolysis
233903_s_at Src domain-containing guanine exchange factor SGEF
c 6.1 Rho protein signaling
207034_s_at GLI-Kruppel family member GLI2 GLI2 6.1 morphogenesis
222853_at fibronectin leucine rich transmembrane protein 3 FLRT3 6.1 cell adhesion
226436_at Ras association (RalGDS/AF-6) domain family 4 RASSF4 6.0 signal transduction
219872_at chromosome 4 open reading frame 18 C4orf18 5.9 —
211966_at collagen, type IV, alpha 2 COL4A2 5.8 ECM organization
209859_at tripartite motif-containing 9 TRIM9 5.8 —
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Molecular Melanoma Signatures
PLoS ONE | www.plosone.org 9 July 2007 | Issue 7 | e594Normal human primary melanocytes were isolated from neonatal
foreskins and grown in complete melanocyte growth medium (Cell
Applications, Cat. No., 135–500). The complete melanocyte
growth medium is consisted of the melanocyte basal medium
(Cell Applications, Cat. No. 134-500) and growth supplement
cocktails containing hydrocortisone (0.5 mg/ml), insulin (5 mg/ml),
12-O-tetradecanoylphorbol-13-acetate (10 ng/ml), bovine pitui-
tary extract (21 mg/ml), bFGF (1 ng/ml), heparin (1 mg/ml), FBS
(0.5 %), gentamycin sulfate (50 mg/ml), amphotericin B (5 ng/ml),
and NaCl (45 mM).
Gene Expression Profiling
Total RNA was isolated from exponentially growing melanoma
cell lines using RNeasy column purification per manufacturer’s
protocol (Qiagen). Two sets of short-term cultured (2 to 3 passage
numbers) normal human melanocytes were prepared from neo-
natal foreskins. In order to minimize genetic variability melano-
cytes from 4–5 individuals were pooled for each culture. Total
RNA from normal melanocytes was extracted and purified by
a combination of phase extraction and chromatography using
TRIzol reagent (Invitrogen Life Technologies Inc.) and RNeasy
columns (Qiagen) in order to remove melanin. In brief,
exponentially growing melanocytes were lysed with TRIzol
reagent and lysate was incubated at 65uC for 2 minutes to
inactivate melanin. Lysate was then subjected to phase extraction
and RNeasy column purification. RNA quality checks, double
strand complementary DNA synthesis, hybridization with Human
Genome U133 Plus 2.0 Array Chips (Affymetrix Inc. Santa Clara,
CA), and initial data extraction were performed at The Gene
Array Core Facility in the Malaria Research Institute (JHMRI) at
The Johns Hopkins Bloomberg School of Public Health (http://
malaria.jhsph.edu/jhmri/resources_education/gene_array_core).
Data Extraction and Statistical Analysis
SAM [19], Gene Cluster 3.0 [58] and TreeView (http://bonsai.ims.
u-tokyo.ac.jp/,mdehoon/software/cluster/index.html), Access,
and Excel (Microsoft, Seattle, WA) programs were used. For all of
the statistical analysis beyond the initial description of datasets,
microarray data were normalized (Dataset S1) and a subset of the 12
microarray data (10 from melanoma cell lines and 2 from normal
human melanocytes) was obtained by filtering to require each gene
probe to have at least one observation in the expression intensity
resulting in a ‘present’ call from all 12 samples. This produced
a subset of data containing a total of 32,632 affymetrix gene probes
(Dataset S2). This filtered subset of data was used for all of the
additional analysis. Cluster Analysis. Unsupervised hierarchical
clustering analysis was performed on the subset of data (without
log transformation) with Gene Cluster 3.0 (http://bonsai.ims.u-
tokyo.ac.jp/,mdehoon/software/cluster/index.html) by using the
correlation (uncentered) similarity metric and centeroid linkage
clustering method. The resulting tree-images were visualized using
Java TreeView. Statistical Analysis of Microarray (SAM). SAM was
performed on the subset of array data without log transformation
using SAM software package. Groups are defined based on the
hierarchical clustering; for example, group 1 = less-aggressive
primary melanomas (RGP melanomas: WM35, Sbcl2, WM1552C
and VGP melanomas: WM902B and WM278), and group 2 =
aggressive metastatic melanomas (Metastatic melanomas: WM852,
WM983B, and 1205Lu; and VGP melanomas: WM983A and
WM793) as seen Figure 1. Delta was chosen to limit the output gene
list so that minimum predicted false-positives would be included.
Three-step Data Reduction Algorithm. In order to identify melanoma
invasion-specific gene signature, uniquely designed three-step data
reduction algorithm was applied to the subset of expression data.
First step is that the proveset should be called as ‘present’ in three
samples out of four VGP melanoma cells and two samples out of
three RGP melanoma cells. Second step is that the candidate
proveset should be expressed five folds or more in VGP melanoma
cell lines than RGP melanoma cell lines. The last step is that the
gene probesets were retained only when the expression level is
greater than three folds in VGP melanoma cell lines compared to
that of primary human melanocytes. The last step is implemented
because the candidate gene expression level should be higher if the
gene products have certain degree of functional roles in the invasion
processes of malignant melanoma. The probesets, those that pass
through three-step filtration criteria are subjected to probeset to gene
mapping using NetAffx, a web interface program from Affymetrix
Inc. Gene annotation for the gene mane, gene symbol, and GO
Biological Procession Analysis also performed by the NetAffx.
Quantitative Real-time PCR
cDNA was generated by using the SuperScript
TM First-Strand
Synthesis System for RT-PCR according to manufacturers
instructions (Invitrogen, Carlsbad, CA). Quantitative real-time
PCR was performed with an Applied Biosystems Prism 7900 HT
Sequence Detection System using SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA). The thermal cycling
conditions for quantitative real-time RT-PCR analysis to validate
gene expression changes were as follows: hold for 10 minutes at
95uC, followed by three-step PCR for 40 cycles of 95uC for
15 seconds, 55uCt o6 0 uC for 25 seconds, and 72uC for
30 seconds. Optimal annealing temperatures were predetermined
Probe Set ID Gene Title Gene Symbol Fold
b Biological Process
214023_x_at tubulin, beta 2B TUBB2B 5.7 microtubule-based movement
204702_s_at nuclear factor (erythroid-derived 2)-like 3 NFE2L3 5.7 regulation of transcription
205599_at TNF receptor-associated factor 1 TRAF1 5.6 signal transduction
212325_at hypothetical protein, DKFZP686A01247 — 5.6 actomyosin organization
1554474_a_at monooxygenase, DBH-like 1 MOXD1 5.6 catecholamine metabolism
235116_at TNF receptor-associated factor 1 TRAF1 5.2 signal transduction
210139_s_at peripheral myelin protein 22 PMP22 5.1 peripheral nervous develop
203680_at protein kinase, cAMP-dependent, type II, beta PRKAR2B 5.0 signal transduction
aGenes with greater than five-fold upregulation are shown.
bFold represents average expression ratio of VGP melanoma cells over RGP melanoma cells.
cGene with multiple probesets are shown with a representative probeset.
doi:10.1371/journal.pone.0000594.t003
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 3. Cont.
..................................................................................................................................................
Molecular Melanoma Signatures
PLoS ONE | www.plosone.org 10 July 2007 | Issue 7 | e594to ensure single amplified product. All samples were performed in
triplicate. Amplification data were analyzed with an Applied
Biosystems Prism Sequencer Detection Software Version 2.3
(Applied Biosystems, Forster City, CA). Human GAPDH gene was
used as endogenous control. To normalize the relative expression
of the genes of interest to the GAPDH control, standard curves
were prepared for each gene and GAPDH in each experiment.
Semi-quantitative Duplex PCR
Semi-quantitative duplex RT-PCR was performed by an MJ
Research Programmable Thermal Controller (PTC-100, Inc.,
Watertown, MA) and the amplified products were separated on an
agarose gel. Our duplex PCR utilized 20 bp oligonucleotides to
amplify regions of 300–400 bp from the genes of interest. Intitial
optimization experiments were conducted to establish the most
favorable primer concentrations between the genes of interest and
internal control GAPDH, yielding 0.8 mM and 0.04 mM, re-
spectively. The PCR was carried out in a total volume of 25 mL,
containing 2.5 mL of 10X PCR Buffer (containing 15 mM
MgCl2), 0.2 mM dNTPs, and 0.3 ul AmpliTaq Gold DNA
Polymerase (Applied Biosystems, Foster City, CA). Thirty to
thirty-five amplification cycles were performed by an MJ Research
Programmable Thermal Controller (PTC-100, Inc., Watertown,
MA), using a denaturing temperature of 95uC for 25 seconds, an
annealing temperature varying between 55uC260uC (depending
on gene) for 30 seconds, and primer extension at 72uC for
30 seconds. Each amplification experiment also included two
negative PCR controls, a no-RNA control from reverse transcrip-
tion procedures and a no-cDNA water control. Following
amplification, 25 mL of the samples were separated via electro-
phoresis on a 3% agarose gel. The primer sequences were
designed by using Primer3, primer analysis software (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), yielded only one
amplified product and had the following sequences:
Immunofluorescence Labeling
RGP and VGP Cells were plated on glass slides and cultured in
melanocyte growth media overnight without any stimulation. Cells
were fixed at room temperature for 15 minutes using 3.5% para-
formaldehyde solution. Cells were washed briefly with PBS and
then permeabilized with either 0.5% Triton X-100 for 10 minutes
or 220uC cooled methanol for 15 minutes. Slides were blocked
with 16% normal goat serum (Santa Cruz Biotech., Santa Cruz,
CA) for 1 hour and then incubated with rabbit polyclonal IgG p65
antibody (Santa Cruz Biotech., Santa Cruz, CA) at 1:100 dilution.
Subsequent to overnight incubation at 4uC, the slides were washed
with PBS and incubated with goat anti-rabbit IgG-Alexa 594
(Molecular Probes Eugene, OR) at 1:200 dilution at room
temperature for 1 hour. Stained slides were washed with PBS
and viewed under a fluorescence microscope (Eclipse TS100,
Nikon, Tokyo, Japan).
Gene Transcription Promoter Analysis
Transcription factor binding cis element sequence profiling in the
selected gene promoter was performed by using a web tool known
as TESS (Transcription Element Search System, http://www.cbil.
upenn.edu/tess). Each genes promoter sequences from the
transcription start site up to 2.0 kb of upstream of the genes were
subjected to the TESS and screened by TRANSFAC database to
identify matched consensus sequences of known DNA binding
transcription factors.
SUPPORTING INFORMATION
Dataset S1 A combined and normalized raw dataset from the
12 sets of microarray data (two sets of primary human melanocytes
and ten melanoma cell lines).
Found at: doi:10.1371/journal.pone.0000594.s001 (18.02 MB
DOC)
Dataset S2 A subset of the 12 microarray data (10 from
melanoma cell lines and 2 from human primary melanocytes) was
obtained by filtering to require each Affymetrix probe to have at
least one observation in the expression intensity resulting in
a present call from all 12 samples.
Found at: doi:10.1371/journal.pone.0000594.s002 (4.50 MB
DOC)
Table S1 Results of SAM analysis between Group 1 and Group
2 melanoma cells. The results include the SAM Output showing
the list of Affymetrix probesets and associated gene symbols that
are differentially expressed in the two groups of melanoma cell
lines.
Found at: doi:10.1371/journal.pone.0000594.s003 (3.20 MB
DOC)
Table S2 Results of SAM analysis between HPMs and Group 2
melanoma cells. The results include the SAM Output showing the
list of Affymetrix probesets and associated gene symbols that are
downregulated in Group 2 melanoma cell lines.
Found at: doi:10.1371/journal.pone.0000594.s004 (3.05 MB
DOC)
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MELK Forward: 59-TGGCTCTCTCCCAGTAGCAT-39
Reverse: 59-TAGCACTGGCTTGTCCACAG-39
GINS4 Forward: 59-CAGAGAGTTCATGGCGAACA-39
Reverse: 59-CTCCCAAAGTGCTGGGATTA-39
NCAPG Forward: 59-TATTGGTGTGCCCTTTGTGA-39
Reverse: 59-CAGGGATATTGGGATTGTGG-39
CDH3 Forward: 59-ACGACACCCTCTTGGTGTTC-39
Reverse: 59-GTCAAACTGCCCACATTCCT-39
KIT Forward: 59-TGACTTACGACAGGCTCGTG-39
Reverse: 59-AAGGAGTGAACAGGGTGTGG-39
DPP4 Forward: 59-CAAATTGAAGCAGCCAGACA-39
Reverse: 59-CAGGGCTTTGGAGATCTGAG-39
SYR Forward: 59-GAAGCCATATCGAGGGATGA-39
Reverse: 59-TGACAAGTTGTGGGCATGTT-39
CXCL1 Forward: 59-TGTTTGAGCATCGCTTAGGA-39
Reverse: 59-GATCTCATTGGCCATTTGCT-39
CXCL2 Forward: 59-TTGCGCCTAATGTGTTTGAG-39
Reverse: 59-ATACATTTCCCTGCCGTCAC-39
IL8 Forward: 59-AGGGTTGCCAGATGCAATAC-39
Reverse: 59-AGCAGACTAGGGTTGCCAGA-39
IGFBP3 Forward: 59-GCTACAGCATGCAGAGCAAG-39
Reverse: 59-AACATGTGGTGAGCATTCCA-39
GAPDH Forward: 59-GATCATCAGCAATGCCTCCT-39
Reverse: 59-TTCAGCTCAGGGATGACCTT-39
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